Our Science

Our company develops innovative cell therapies for autoimmune diseases.


Autoimmunology

The therapeutic area in which PolTREG therapies are used is autoimmune diseases: that is, diseases in which the immune system attacks the person’s own body.

There are up to 100 diseases that are in this group, and most of them are chronic diseases with worsening complications over time. These are currently incurable diseases, and available treatments are often only able to delay the progression of the disease. The Company’s TREGs and TREGs combination therapies under development aim to halt progress of these diseases in the pre-symptomatic or early stages, and to improve the quality of life for patients with more advanced disease.

 


Cell therapies

Cell therapies involve the use of human cells to regenerate a patient’s damaged tissues or organs.

These cells can come from the same patient. This method differs from transplants in that it does not use whole organs or tissues, but isolated, purified and sometimes modified cells. PolTREG is active in the areas of cell therapies and genetically modified cell therapies. Living-cell therapies are one of the most promising groups of new medicines offering hope to solve some unmet medical needs for currently incurable diseases.

Pipeline

PolTREG develops proprietary cell therapies in the area of autoimmune diseases.

The four most advanced PolTREG projects are already in the clinical stage of development in the areas of type 1 diabetes and multiple sclerosis. The portfolio also includes projects based on a new generation of genetically modified T-regulatory lymphocytes.

Therapeutic area

Indication

Discovery

Preclinical

Phase I

Phase II

Phase III

Type 1 diabetes

Early onset (stage 3)

PTG-007+ / rituximab

Presymptomatic (stage 1/2)

PTG-007+ / rituximab

Multiple sclerosis

Relapsing-remitting (RRMS)

PTG-007+ / routinely used MS drug

Primary progressive (PPMS)

PTG-007+ / routinely used MS drug

NEXT-GENERATION
ENGINEERED TREGS

Multiple sclerosis

Amyotrophic Lateral Sclerosis

RRMS / PPMS

CAR-TREGs

CAR-TREGs

Type 1 diabetes

Early onset (stage 1-3)

PTG-020

Early onset (stage 1)

TCR-TREGs


Major publications

2024

PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration

Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity

2022

Combined therapy with CD4+CD25highCD127 T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial

Mesenchymal stem cells transfer mitochondria to allogeneic TREGs in an HLA-dependent manner improving their immunosuppressive activity

2021

Administration of CD4+CD25 high CD127−FoxP3+ Regulatory T Cells for Relapsing‑Remitting Multiple Sclerosis: A Phase 1 Study

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy

2020

Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies

Proinsulin-­specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy

2018

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization

2017

Cell-Based Therapies with T Regulatory Cells

Mild hypothermia provides TREG stability

2016

Factors affecting long‑term efficacy of T regulatory cell‑based therapy in type 1 diabetes

2015

Hurdles in therapy with regulatory T cells

2014

Therapy of type 1 diabetes with CD4+ CD25 high CD127-regulatory T cells prolongs survival of pancreatic islets — Results of one year follow-up

2012

Administration of CD4+CD25 high CD1272 Regulatory T Cells Preserves b-Cell Function in Type 1 Diabetes in Children

2011

The Time Is Crucial for Ex Vivo Expansion of T Regulatory Cells for Therapy

2009

First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− Tregulatory cells

2008

Ex Vivo Expansion of CD4+CD25+ T Regulatory Cells for Immunosuppressive Therapy